Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209000 · ClinicalTrials.gov registry record
Nephrotic Syndrome Study Network
A clinical trial of Membranous Nephropathy and Glomerulosclerosis, Focal Segmental, sponsored by University of Michigan.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 20
- Study locations
NCT01209000 is a study of Membranous Nephropathy and Glomerulosclerosis, Focal Segmental that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 1,200 participants, above the 135-participant average among 5 other Membranous Nephropathy trials with a reported enrollment target (789% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT01209000, a study of Membranous Nephropathy and Glomerulosclerosis, Focal Segmental, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients. In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium. Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.
Conditions Studied
Interventions
- PROCEDURE Kidney Biopsy
Study Locations (20)
California
- University of Southern California-Children's Hospital - Los Angeles
- Stanford University School of Medicine - Palo Alto
- University of California San Francisco Benioff Children's Hospitals - San Francisco
- Lundquist Biomedical Research Institute at Harbor UCLA Medical Center - Torrance
New York
- Cohen Children's Hospital - New Hyde Park
- New York University Medical Center - New York
- Bellevue Hospital - New York
Colorado
- Children's Hospital Colorado - Aurora
- University of Colorado Anschutz School of Medicine - Aurora
Maryland
- Johns Hopkins Medical Institute - Baltimore
- Kidney Disease Section, NIDDK, NIH - Bethesda
Michigan
- CS Mott Children's Hospital, University of Michigan - Ann Arbor
- University of Michigan Medical Center - Ann Arbor
Missouri
- Children's Mercy Hospital - Kansas City
- Washington University - St Louis - St Louis
Florida
- University of Miami Miller School of Medicine - Miami
Georgia
- Emory University and Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2010-04 |
| Est. Completion | 2029-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209000
The ClinicalTrials.gov registry entry for NCT01209000 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 135-participant average among 5 other Membranous Nephropathy trials with a reported enrollment target (789% higher). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Membranous Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Kidney Biopsy is the first listed.
NCT01209000 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT01209000 about?
NCT01209000 is a clinical study titled "Nephrotic Syndrome Study Network". Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than ...
What is the current status of trial NCT01209000?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2010-04. Estimated completion is 2029-06-30.
What conditions does trial NCT01209000 study?
This clinical trial studies the following conditions: Membranous Nephropathy, Glomerulosclerosis, Focal Segmental, Minimal Change Disease (MCD).
What interventions are being tested in trial NCT01209000?
The interventions under investigation include: Kidney Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01209000?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01209000 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belimumab With Rituximab for Primary Membranous Nephropathy
RECRUITING · Phase 2
-
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
RECRUITING
-
NEPTUNE Match Study
RECRUITING · NA
-
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 1
-
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
COMPLETED · Phase 2
Explore more on PlainTrial
Membranous Nephropathy
All registered trials for this condition
Glomerulosclerosis, Focal Segmental
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.